Phase 1 Study of Anti-PD-1 Antibody MK-3475 and Peginterferon Alfa-2b for Advanced Melanoma
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-020
- 25 Oct 2018 Results (data cutoff date: 31 Dec 2017), published in the Journal of Clinical Oncology.
- 07 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Aug 2018 Planned primary completion date changed from 1 Aug 2016 to 1 Apr 2019.